Aratana Therapeutics (PETX) Tops Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PETX Hot Sheet
Join SI Premium – FREE
Aratana Therapeutics (NASDAQ: PETX) reported Q2 EPS of ($0.23), $0.15 better than the analyst estimate of ($0.38).
"We continue to be on-track with our objective of having six products on the market in 2016 with a deep pipeline of additional therapeutics potentially coming to market behind those," stated Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics. "We are very excited about the outcomes we have achieved in our development programs."
For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- Leidos Holdings (LDOS) PT Lowered to $138 at Stifel
- Neuronetics (STIM) Tops Q3 EPS by 7c
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
